Advertisement
Advertisement
U.S. markets open in 5 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cassiopea S.p.A. (CPPSF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
35.150.00 (0.00%)
At close: 09:57AM EST
Advertisement

Cassiopea S.p.A.

Via Cristoforo Colombo, 1
Lainate, MI 20020
Italy
39 02 86 89 11 24
https://www.cassiopea.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Pierpaolo GuzzoCFO & Exec. Chairman43.93kN/A1968
Ms. Diana HarbortCEO, Head of Investor Relations & Exec. Director665.47kN/A1966
Mr. Marco PaseroChief Operating OfficerN/AN/A1966
Dr. Luigi MoroChief Scientific OfficerN/AN/A1951
Dr. Alessandro MazzettiChief Medical OfficerN/AN/A1952
Ms. Martina CartwrightSr. Director of Medical AffairsN/AN/A1968
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy. As of December 2, 2021, Cassiopea S.p.A. operates as a subsidiary of Cosmo Pharmaceuticals N.V.

Corporate Governance

Cassiopea S.p.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement